Eisai Co Ltd
Bristol Myers Squibb says Alzheimer’s is the biggest market for new schizophrenia drug
The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, US, on Wednesday, Dec. 27, 2023. Adam Glanzman | Bloomberg | Getty Images Bristol Myers Squibb believes Alzheimer’s is the largest market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in revenue. In […]
Read More
Biogen tops estimates, raises profit guidance as Alzheimer’s drug Leqembi gains traction
A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021. Dado Ruvic | Reuters Biogen on Wednesday reported third-quarter revenue and adjusted earnings that topped expectations while raising its full-year profit guidance, as sales of its breakthrough Alzheimer’s drug, Leqembi, and other new products gain traction. […]
Read More
5 things to know before the stock market opens Monday
Here are the most important news items that investors need to start their trading day: 1. Looking for a rebound Stock futures ticked higher Monday after equities tumbled last week. The S&P 500 dropped 4.3% for the period, its worst week since 2023. The Nasdaq Composite shed 5.8% in its poorest week since 2022, and […]
Read More
Alzheimer’s drug Leqembi promises to give patients more time, but they face a long road to treatment
Hannah Yoon | The Washington Post | Getty Images Leqembi, an Alzheimer’s drug from Biogen and Eisai, isn’t a cure for the mind-damaging disease. But the treatment promises to give patients such as Missie Meeks more time to live their daily lives normally and independently of others. Meeks, an English professor based in Ellisville, Mississippi, […]
Read More
Patients on Alzheimer’s drug Leqembi see benefits over three years, Eisai study says
The newly FDA approved Alzheimer’s treatment Leqembi is prepared at Abington Neurological Associates in Abington, PA., on Tuesday, November 7, 2023. Hannah Yoon | The Washington Post | Getty Images The breakthrough Alzheimer’s drug Leqembi slowed disease progression in patients over three years, demonstrating the need for them to stay on the treatment long term, […]
Read More
Older GLP-1 drug from Novo Nordisk may slow Alzheimer’s disease progression by protecting the brain, study says
A box of the drug Victoza, made by Novo Nordisk Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020. George Frey | Reuters An older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer’s disease by protecting patients’ brains, according to data […]
Read More
European drug regulator rejects Alzheimer’s treatment Leqembi from Biogen, Eisai
European drug regulators on Friday rejected the Alzheimer’s treatment Leqembi from Biogen and Eisai, creating another hurdle for the companies as they scramble to boost uptake of the therapy in the U.S. The European Commission, the EU’s executive body, has a final say in Leqembi’s approval. But it almost always follows the drug regulator’s recommendations. […]
Read More
Biogen tops profit estimates as cost cuts take hold, Alzheimer’s drug Leqembi launch picks up
A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021. Dado Ruvic | Reuters Biogen on Wednesday reported first-quarter profit that topped estimates as the company’s cost-cutting efforts took hold and sales of its closely watched Alzheimer’s drug, Leqembi, came in higher than expected. Biogen and […]
Read More
Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move
Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval. AJ Mast | Bloomberg | Getty […]
Read More
Healthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow start
Good afternoon! The launch of the closely watched Alzheimer’s drug Leqembi is off to a slow start. Still, demand for the treatment from Biogen and its Japanese partner Eisai is rising. That’s the update the two drugmakers gave Wall Street during their latest quarterly earnings calls earlier this month. But before we get into the numbers, […]
Read More